Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration (FDA) approved durvalumab for certain types of bladder, lung, and biliary tract cancer: [6] [13] [14]. Adults with locally advanced or metastatic urothelial carcinoma who either have disease progression during or following platinum-containing chemotherapy or have disease progression within twelve months of neoadjuvant or adjuvant treatment with platinum ...
Cholangiocarcinoma, also known as bile duct cancer, is a type of cancer that forms in the bile ducts. [2] Symptoms of cholangiocarcinoma may include abdominal pain , yellowish skin , weight loss , generalized itching , and fever. [ 1 ]
A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree) occurring at the confluence of the right and left hepatic bile ducts. The disease was named after Gerald Klatskin, who in 1965 described 15 cases and found some characteristics for this type of cholangiocarcinoma.
Cholangiocarcinoma also has a significant geographical distribution, with Thailand showing the highest rates worldwide due to the presence of liver fluke. [ 47 ] [ 78 ] In the United States, there were 42,810 new cases of liver and intrahepatic bile duct cancer in 2020, which represents 2.4% of all new cancer cases in the United States. [ 79 ]
The search engine that helps you find exactly what you're looking for. Find the most relevant information, video, images, and answers from all across the Web.
Primary sclerosing cholangitis is one of the major known risk factors for cholangiocarcinoma, [40] a cancer of the biliary tree, for which the lifetime risk among patients with PSC is 10-15%. [3] This represents a 400-fold greater risk of developing cholangiocarcinoma compared to the general population. [ 1 ]
Main page; Contents; Current events; Random article; About Wikipedia; Contact us
Tremelimumab is indicated, in combination with durvalumab, for the treatment of adults with unresectable hepatocellular carcinoma. [7] [11] [8]Tremelimumab in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer with no sensitizing epidermal growth factor receptor mutations or anaplastic ...